These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 26515736)

  • 1. The Role of Antiangiogenic Therapy in the Development of Osteonecrosis of the Jaw.
    Fantasia JE
    Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):547-53. PubMed ID: 26515736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors.
    Dodson TB
    Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):509-16. PubMed ID: 26362367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
    Turner B; Drudge-Coates L; Ali S; Pati J; Nargund V; Ali E; Cheng L; Wells P
    Urol Nurs; 2016; 36(3):111-6, 154. PubMed ID: 27501591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Denosumab and anti-angiogenetic drug-related osteonecrosis of the jaw: an uncommon but potentially severe disease.
    Sivolella S; Lumachi F; Stellini E; Favero L
    Anticancer Res; 2013 May; 33(5):1793-7. PubMed ID: 23645723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiresorptive drug-related osteonecrosis of the jaw.
    Uyanne J; Calhoun CC; Le AD
    Dent Clin North Am; 2014 Apr; 58(2):369-84. PubMed ID: 24655528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medication-related osteonecrosis of the jaw: An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention.
    Owosho AA; Liang STY; Sax AZ; Wu K; Yom SK; Huryn JM; Estilo CL
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 May; 125(5):440-445. PubMed ID: 29580668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnosis and Staging of Medication-Related Osteonecrosis of the Jaw.
    Ruggiero SL
    Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):479-87. PubMed ID: 26293329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenvatinib and osteonecrosis of the jaw: A pharmacovigilance study.
    Lu W; Guo Q; Ma Z; Liu L; Zhao Z
    Eur J Cancer; 2021 Jun; 150():211-213. PubMed ID: 33934057
    [No Abstract]   [Full Text] [Related]  

  • 9. Osteonecrosis of the jaw and the role of macrophages.
    Pazianas M
    J Natl Cancer Inst; 2011 Feb; 103(3):232-40. PubMed ID: 21189409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone.
    Christodoulou C; Pervena A; Klouvas G; Galani E; Falagas ME; Tsakalos G; Visvikis A; Nikolakopoulou A; Acholos V; Karapanagiotidis G; Batziou E; Skarlos DV
    Oncology; 2009; 76(3):209-11. PubMed ID: 19212145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.
    Guarneri V; Miles D; Robert N; Diéras V; Glaspy J; Smith I; Thomssen C; Biganzoli L; Taran T; Conte P
    Breast Cancer Res Treat; 2010 Jul; 122(1):181-8. PubMed ID: 20361252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Denosumab, an Alternative to Bisphosphonates but also Associated with Osteonecrosis of the Jaw--What is the Risk?
    Sidhu HK
    Dent Update; 2015 Jun; 42(5):436-8, 440. PubMed ID: 26964445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Denosumab and osteonecrosis of the jaws - the pharmacology, pathogenesis and a report of two cases.
    O'Halloran M; Boyd NM; Smith A
    Aust Dent J; 2014 Dec; 59(4):516-9. PubMed ID: 25131835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients.
    Hoff AO; Toth B; Hu M; Hortobagyi GN; Gagel RF
    Ann N Y Acad Sci; 2011 Feb; 1218():47-54. PubMed ID: 20946574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medication-related osteonecrosis of the jaw unrelated to bisphosphonates and denosumab-a review.
    King R; Tanna N; Patel V
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2019 Apr; 127(4):289-299. PubMed ID: 30713092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology.
    Fusco V; Santini D; Armento G; Tonini G; Campisi G
    Expert Opin Drug Saf; 2016 Jul; 15(7):925-35. PubMed ID: 27074901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
    Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medication-Related Osteonecrosis of the Jaw: Basic and Translational Science Updates.
    Allen MR
    Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):497-508. PubMed ID: 26277349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients with bisphosphonates-associated osteonecrosis of the jaw have reduced circulating endothelial cells.
    Allegra A; Oteri G; Nastro E; Alonci A; Bellomo G; Del Fabro V; Quartarone E; Alati C; De Ponte FS; Cicciù D; Musolino C
    Hematol Oncol; 2007 Dec; 25(4):164-9. PubMed ID: 17577204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Notoriety bias in a database of spontaneous reports: the example of osteonecrosis of the jaw under bisphosphonate therapy in the French national pharmacovigilance database.
    de Boissieu P; Kanagaratnam L; Abou Taam M; Roux MP; Dramé M; Trenque T
    Pharmacoepidemiol Drug Saf; 2014 Sep; 23(9):989-92. PubMed ID: 24737486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.